Santhera Signs a Clinical Trial Agreement with Cold Spring Harbor Laboratory to Evaluate Lonodelestat (POL6014) Against Acute Respiratory Distress Syndrome Associated with COVID-19

 Santhera Signs a Clinical Trial Agreement with Cold Spring Harbor Laboratory to Evaluate Lonodelestat (POL6014) Against Acute Respiratory Distress Syndrome Associated with COVID-19

Santhera Signs a Clinical Trial Agreement with Cold Spring Harbor Laboratory to Evaluate Lonodelestat (POL6014) Against Acute Respiratory Distress Syndrome Associated with COVID-19

Shots:

  • Santhera to provide its lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program and validates hNE as a target and shed light on lonodelestat as a potential therapy against COVID-19
  • Researchers at CSHL are part of the consortium of international non/clinical experts called the ‘NETwork to target neutrophils in COVID-19’. The NETwork will evaluate the role of neutrophils and NETs in the pathology of COVID-19 and hNE along with other targets to treat COVID-19
  • Lonodelestat (POL6014) is a selective hNE inhibitor and has completed its P-I single-dose escalation studies in healthy volunteers and patients with CF and is currently investigated in a multiple ascending dose study in CF patients

Click here ­to­ read full press release/ article | Ref: Santhera | Image: Medgazette

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post